SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotechnology Value Fund, L.P. -- Ignore unavailable to you. Want to Upgrade?


To: SnowShredder who wrote (578)4/7/1999 11:22:00 AM
From: Jorgen JensenRead Replies (1) | Respond to of 4974
 
I know this news pales in comparison to the previous post,
but I am just doing my part of submitting obscure news, and
of course hoping for a vote or two...

BRISBANE, Australia--(BW HealthWire)--April 7, 1999-- Progen Industries Ltd. (Nasdaq:PGLAF - news; ASX:PGL) reported today that preliminary studies
conducted at the University of Queensland and the John Curtin School of Medical Research, Canberra, show that Progen's novel heparanase inhibitor, when used in
experimental models that mimic vascular damage associated with angioplasty, significantly moderates the narrowing of the coronary artery.

More info at biz.yahoo.com